Aurobindo Pharma Limited (NSE:AUROPHARMA)
India
· Delayed Price · Currency is INR | Market Cap | 666.64B |
| Revenue (ttm) | 317.24B |
| Net Income (ttm) | 34.86B |
| Shares Out | 580.80M |
| EPS (ttm) | 59.81 |
| PE Ratio | 19.19 |
| Forward PE | 16.44 |
| Dividend | 3.00 (0.25%) |
| Ex-Dividend Date | n/a |
| Volume | 1,847,211 |
| Average Volume | 1,094,457 |
| Open | 1,189.50 |
| Previous Close | 1,191.20 |
| Day's Range | 1,143.80 - 1,190.70 |
| 52-Week Range | 1,010.00 - 1,592.00 |
| Beta | 0.25 |
| RSI | 42.81 |
| Earnings Date | May 28, 2025 |
About Aurobindo Pharma
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibi... [Read more]
Financial Performance
In 2024, Aurobindo Pharma's revenue was 317.24 billion, an increase of 9.39% compared to the previous year's 290.02 billion. Earnings were 34.86 billion, an increase of 9.86%.
Financial StatementsNews
Aurobindo Pharma shares fall over 2% after Citi maintains ‘Sell’ rating, cuts target price to Rs 1,100
Aurobindo Pharma shares fell over 2% after Citi maintained a ‘Sell’ rating and lowered its target price to ₹1,100. Citi expressed concerns about flattening growth in the US market and rising margin pr...
Motilal Oswal retains ‘Buy’ on Aurobindo Pharma, sets target at Rs 1,370 on strong EU presence, growth visibility
Motilal Oswal has maintained a Buy rating on Aurobindo Pharma with a target price of ₹1,370, citing strong Q4 performance, recovery in production, and growth traction in European markets. The brokerag...
Nuvama cuts Aurobindo Pharma target to Rs 1,485 but retains ‘Buy’ on healthy EBITDA margin
Nuvama Institutional Equities has retained its Buy rating on Aurobindo Pharma (ARBP) but revised its target price down to ₹1,485 from ₹1,677, citing a mixed Q4 performance and a cautious FY26 outlook....
Stocks to watch today on May 28: LIC, Aurobindo Pharma, Info Edge among top brokerage picks
Brokerage firms have released fresh research notes on key Indian stocks post Q4FY25 earnings. Life Insurance Corporation of India (LIC), Aurobindo Pharma, and Info Edge are among the most discussed, w...
CLSA trims FY26-27 estimates for Aurobindo Pharma after Pen-G plant disruption
CLSA has reiterated its ‘Outperform’ rating on Aurobindo Pharma, with a target price of ₹1,400, following its highest-ever revenue and EBITDA performance in Q4FY25. Revenue rose to ₹8,382 crore, while...
HSBC advises to Buy Aurobindo Pharma, says long-term outlook intact despite EBITDA miss
HSBC has maintained a ‘Buy’ rating on Aurobindo Pharma, setting a target price of ₹1,415. The company posted an in-line revenue performance in Q4FY25 but missed on EBITDA due to higher-than-expected o...
Goldman Sachs retains ‘Buy’ on Aurobindo Pharma, sees value in stock despite gRevlimid headwinds
Goldman Sachs has reaffirmed its ‘Buy’ call on Aurobindo Pharma with a target price of ₹1,275, viewing the Q4FY25 results as decent despite upcoming challenges. Revenue came in at ₹8,382 crore, up 10....
Citi maintains ‘Sell’ on Aurobindo Pharma after Q4 results, trims earnings estimates on margin risks post gRevlimid
Citi has maintained a ‘Sell’ rating on Aurobindo Pharma and cut its target price to ₹1,100, flagging concerns around flattening growth in the US market and rising margin risks in the coming quarters. ...
Top stocks to watch today, May 27: Lupin, Aurobindo Pharma, NHPC, KEC International, Shilpa Medicare and more
Indian benchmark indices ended higher on Monday, May 26, 2025, supported by positive domestic and global cues. The BSE Sensex gained 455.37 points (0.56%) to close at 82,176.45, while the NSE Nifty50 ...
Q4 earning results today: Aurobindo, Gillette, KEC, FirstCry among key earnings to watch on 26 May
More than 50 listed companies are set to declare their Q4FY25 earnings on 26 May 2025, keeping the focus squarely on stock-specific action. Key companies scheduled to report include Aurobindo Pharma, ...
These Analysts Boost Their Forecasts On Acadia Pharmaceuticals
ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) announced a favorable court ruling on Friday . The U.S. District Court for the District of Delaware upheld the validity and found infringement of Acadia’s ‘7...
PNB, L&T & more: Top stocks on brokers' radar for May 12
Nomura remains positive on CG Power despite margin concerns in its railway business, while Citigroup is bearish on PNB due to profitability and asset quality issues. Citi is optimistic about HPCL, rev...
Top stocks to buy today: Stock market recommendations for May 6, 2025
Stock market recommendations: Mirae Asset Sharekhan suggests buying Aurobindo Pharma, anticipating a breakout from a flag pattern with a target of Rs 1356, and IRCTC, expecting an upward trend to Rs 8...
Aurobindo Pharma shares drop 3% after company reports fire incident at Kakinada plant
Aurobindo Pharma’s stock witnessed a 3% dip following a fire incident at its Penicillin-G manufacturing facility in Kakinada SEZ, Andhra Pradesh. The fire, which occurred near the coal crusher area, c...
Aurobindo Pharma reports fire incident at Andhra Pradesh facility, operations temporarily paused
Aurobindo Pharma Limited on Sunday informed exchanges about a fire incident at one of its manufacturing facilities operated by its wholly owned stepdown subsidiary, Lyfius Pharma Private Limited, loca...
Aurobindo Pharma subsidiary receives positive opinion for biosimilar Dazublys from EMA
CuraTeQ Biologics s.r.o., a subsidiary of Aurobindo Pharma Limited, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a po...
Aurobindo Pharma receives USFDA approval for Dasatinib Tablets; Stock jumps
Aurobindo Pharma’s wholly owned subsidiary, Eugia Pharma Specialities Limited, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Dasatinib Tablets, a...
Aurobindo Pharma gains over 2.5% after USFDA nod for Rivaroxaban tablets in $8.5 billion US market
Shares of Aurobindo Pharma were trading higher in early trade on April 15, 2025, after the company received final approval from the US Food and Drug Administration (USFDA) for its Rivaroxaban tablets,...
Top stocks to watch today, April 15: HDFC Bank, Tata Power, Cyient, IRCON, Vedanta, Aurobindo Pharma and more
Indian stock markets are set to reopen today after an extended weekend, with investors watching closely to see if the bullish momentum from the last session continues. On Friday, benchmark indices reg...
Stocks to watch today: Zydus, Aurobindo, HCL Tech, Tata Power, Indian Hotels, Cyient in focus on expansion and global deals
Stocks of several companies are expected to remain in the spotlight today following a series of announcements related to international expansion, regulatory approvals, and strategic partnerships. Zydu...
Aurobindo Pharma subsidiary receives 11 USFDA observations after North Carolina facility inspection
Aurobindo Pharma Limited has announced the completion of a United States Food and Drug Administration (USFDA) inspection at its Raleigh, North Carolina facility, operated by Aurolife Pharma LLC, a who...
Aurobindo Pharma shares surge over 3% as subsidiary CuraTeQ Biologics reports successful trial results for bone drug BP16
Shares of Aurobindo Pharma jumped 3.69% to ₹1,097.05 on Friday after its biologics arm, CuraTeQ Biologics, announced successful Phase 1 trial results for BP16 — a biosimilar version of denosumab (mark...
Top stocks to watch today, April 11: Tata Steel, Infosys, TCS, BHEL, Aurobindo Pharma, Biocon and more
The Indian stock market could open on a negative note today (Friday, April 11), as indicated by Gift Nifty. At 8:27 AM, Gift Nifty was seen trading at 22,934, down 0.48%. The Indian stock market may o...
Pharma Stocks Falls: Aurobindo Pharma slips 2%, Lupin down 2%, Divi’s Labs falls 3% as Trump reiterates tariffs on pharmaceuticals ‘soon’
Indian pharmaceutical stocks declined in early trade on Wednesday following renewed concerns over potential U.S. import tariffs. At 9:36 AM, Aurobindo Pharma shares were down 2% to ₹1,073.15, Dr. Redd...
Aurobindo Pharma subsidiary secures EU approval for Dyrupeg, a pegylated filgrastim biosimilar
Aurobindo Pharma has achieved a significant milestone with the European Commission (EC) granting marketing authorization for Dyrupeg™, a pegylated filgrastim biosimilar, in the European Union (EU). Th...